Exavir Therapeutics announces entry into a litigation settlement and license agreement for ultra-long-acting HIV compounds with ViiV Healthcare

ViiV Healthcare will make upfront and milestone payments as well as tiered low-to-mid single digit royalties on future sales of ultra-long-acting HIV compounds […]

Read More… from Exavir Therapeutics announces entry into a litigation settlement and license agreement for ultra-long-acting HIV compounds with ViiV Healthcare

Exavir Therapeutics receives $3 million award from NIH / NIAID to advance ultra-long-acting integrase inhibitor XVIR-110

$3M award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institute of Health (NIH), will support the development of XVIR-110 […]

Read More… from Exavir Therapeutics receives $3 million award from NIH / NIAID to advance ultra-long-acting integrase inhibitor XVIR-110

Posted in www

Exavir Therapeutics announces preclinical data demonstrating complete elimination of HIV from human cells with LNP-delivered Tat-targeted CRISPR-Cas9

Exavir Therapeutics, a company dedicated to transforming the lives of patients living with or at risk of acquiring HIV, today announced the publication of preclinical data for XVIR-TAT, Exavir’s proprietary gene editing program in early preclinical development as a potential cure for HIV. […]

Read More… from Exavir Therapeutics announces preclinical data demonstrating complete elimination of HIV from human cells with LNP-delivered Tat-targeted CRISPR-Cas9

Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV

Exavir Therapeutics, a company dedicated to transforming the lives of patients living with or at risk for acquiring HIV and other viral infections, announced today the publication of preclinical data for XVIR-210, an investigational agent being developed as a long-acting antiviral for chronic HBV treatment, HIV treatment and prophylaxis, and HIV-HBV co-infection. […]

Read More… from Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV

Posted in www

Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral

Exavir Therapeutics, a company dedicated to transforming the lives of patients living with or at risk for acquiring HIV, announced today the publication of preclinical data for XVIR-110, an investigational agent being developed as an ultra-long-acting antiretroviral for HIV treatment and prophylaxis. The research findings, published in Nature Communications, detailed additional mechanistic, drug product stability, […]

Read More… from Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral

Posted in www